NEOPHARM, Inc. (NEOL) Tops Q2 EPS by 6c
More News related to NEOL
- NeoPharm Names Dr. Aquilur Rahman as President and CEO
- NeoPharm Submits Application for a Multicenter, Open-Label, Phase II Study of LE-DT for Locally Advanced or Metastatic Pancreatic Cancer Patients as a Frontline Treatment
- NeoPharm (NEOL) Posts Q3 Loss of $0.06
- NeoPharm, Inc. Announces Third Quarter 2009 Financial Results and Clinical Trials Update
- NeoPharm (NEOL) Requests Hearing for Continued Listing on NASDAQ
More News related to Earnings
- Ever-Glory International (EVK) Posts Q3 EPS of $0.14, Better Y/Y
- Houston Wire & Cable (HWCC) Beats Q3 Estimates by 2c
- AVI BioPharma (AVII) Misses Q3 Views by 1c
- Zhongpin (HOGS) Posts Q3 EPS of $0.44, Tops by 6c
- Natco (NTG) Posts Q3 EPS of 41c, Misses Views
NEOPHARM, Inc. (NASDAQ: NEOL) reports a Q2 loss of $0.13, 6 cents better than estimates.
Related Categories
EarningsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
